# Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

> **NCT02292446** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 161 (actual)

## Conditions studied

- Polycythemia Vera

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT02292446
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-21
- **Primary completion:** 2017-12-29
- **Final completion:** 2017-12-29
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2019-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02292446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02292446, "Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02292446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*